Category Archives: Uncategorized

AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

Posted: November 29, 2012 at 4:27 pm

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for … Continue reading

Posted in Uncategorized | Comments Off on AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma